Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30692908 | 1.00 | F2RL3 (0.48) | F2RL3MAPTKMT2AMEN1LMNA | |
| SCHEMBL26983077 | 0.83 | F2RL3 (0.48) | F2RL3MAPTKMT2AMEN1LMNA | |
| SCHEMBL23610639 | 0.80 | MAPT (0.40) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL20183779 | 0.80 | MAPT (0.60) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL20568857 | 0.76 | MAPT (0.43) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL20568611 | 0.75 | MAPT (0.57) | F2RL3MAPTKMT2AMEN1LMNA | |
| SCHEMBL31169742 | 0.75 | MAPT (0.57) | F2RL3MAPTKMT2AMEN1LMNA | |
| SCHEMBL3655462 | 0.75 | F2RL3 (0.50) | F2RL3MAPTKMT2AMEN1LMNA | |
| SCHEMBL20568364 | 0.74 | PLA2G2A (0.55) | MAPTKMT2AMEN1LMNAPOLB | |
| SCHEMBL31735677 | 0.74 | F2RL3 (0.46) | F2RL3MAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630749-B9 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371562-A2 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-3630749-B1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11161839-B2 | 2-quinolone derived inhibitors of BCL6 | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210206756-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-08 | — | — | US | disclosed |
| EP-3630749-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215798-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161839-B2 | 2-quinolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | F2RL3 1522/4885MAPT 4365/4885KMT2A 570/4885 |
| US-20210206756-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | F2RL3 1522/4885MAPT 4365/4885KMT2A 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.